Dissolution rate limited bioavailability of flutamide, and in vitro - In vivo correlation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 49, Issue 1, 2000, Pages 35-39

  Posti, Juhani ^a   Katila, Kirsi ^a   Kostiainen, Timo ^a  

^a Oy Leiras Finland Ab   (Finland)

Author keywords

Bioavailability; Dissolution rate; Flutamide; In vitro in vivo correlation

Indexed keywords

FLUTAMIDE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTICLE SIZE;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FLUTAMIDE; HUMANS; MALE; PARTICLE SIZE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0033987228     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(99)00061-2     Document Type: Article

References (11)

1. Parfitt K. Martindale, Complete Drug Reference. 32nd ed. 1999;537 Pharmaceutical Press, London.
2. Information from the Pharmaceutical Development Laboratory of Leiras, Turku, Finland.
3. Fiese E.F., Hagen T.A. Preformulation. Lachman L., Lieberman H.A., Kanig J.L. The Theory and Practice of Industrial Pharmacy. third ed. 1986;185 Lea and Febiger, Philadelphia.
4. Section 3AQ1a Development pharmaceutics and process validation, Volume 3A: Guidelines, Medicinal products for human use, Quality and biotechnology. European Commission (1998 Edition).
5. Chapter <1088> In vitro and in vivo evaluation of dosage forms, The United States Pharmacopeia 23, 1995, pp. 1924-1929.
6. Erläuterungen des BGA zum Antrag auf Zulassung eines Arzneimittels, 2. Auflage, Bundesgesundheitsamt, 1988, p. 31.
7. Rothe W., Schellhorn J. Bestimmung der Auflösungsrate für das Europäische Arzneibuch. Pharm. Ind. 41:1979;785-789.
8. Shah V.P., et al. In vitro dissolution of sparingly water-soluble drug dosage forms. Int. J. Pharm. 125:1995;99-106.
9. Section 3AQ19a Quality of prolonged release oral solid dosage forms, Volume 3A: Guidelines, Medicinal products for human use, Efficacy. European Commission (1998 Edition).
10. Blume H., Krämer J., Böing B. Zur pharmazeutischen Qualität von Rytmonorm-300-Importpräparaten. Pharm. Ztg. 139:1994;908-912.
11. Blume H., Gundert-Remy U., Schug B., Elze M., Staab A. Bioverfügbarkeit von Rytmonorm-Importen. Pharm. Ztg. 141:1996;4475-4489.